References: Principles of appropriate antimicrobial prescribing

  • Béïque L, Zvonar R. Addressing Concerns about Changing the Route of Antimicrobial Administration from Intravenous to Oral in Adult Inpatients. Can J Hosp Pharm 2015;68(4):318-26. https://pubmed.ncbi.nlm.nih.gov/26327706/
  • Borman AM, Johnson EM. Name Changes for Fungi of Medical Importance, 2018 to 2019. J Clin Microbiol 2021;59(2). https://www.ncbi.nlm.nih.gov/pubmed/33028600
  • Kim JY, Yum Y, Joo HJ, An H, Yoon YK, Kim JH, et al. Impact of antibiotic usage on extended-spectrum beta-lactamase producing Escherichia coli prevalence. Sci Rep 2021;11(1):13024. https://www.ncbi.nlm.nih.gov/pubmed/34158540
  • Landersdorfer CB, Gwee A, Nation RL. Clinical pharmacological considerations in an early intravenous to oral antibiotic switch: are barriers real or simply perceived? Clin Microbiol Infect 2023;29(9):1120-5. https://www.ncbi.nlm.nih.gov/pubmed/37059222
  • McCarthy K, Avent M. Oral or intravenous antibiotics? Aust Prescr 2020;43(2):45-8. https://pubmed.ncbi.nlm.nih.gov/32346210/
  • Nathwani D, Lawson W, Dryden M, Stephens J, Corman S, Solem C, et al. Implementing criteria-based early switch/early discharge programmes: a European perspective. Clin Microbiol Infect 2015;21 Suppl 2:S47-55. https://www.ncbi.nlm.nih.gov/pubmed/26198369
  • Tacconelli E, Gorska A, De Angelis G, Lammens C, Restuccia G, Schrenzel J, et al. Estimating the association between antibiotic exposure and colonization with extended-spectrum beta-lactamase-producing Gram-negative bacteria using machine learning methods: a multicentre, prospective cohort study. Clin Microbiol Infect 2020;26(1):87-94. https://www.ncbi.nlm.nih.gov/pubmed/31128285
  • Zhu FH, Rodado MP, Asmar BI, Salimnia H, Thomas R, Abdel-Haq N. Risk factors for community acquired urinary tract infections caused by extended spectrum beta-lactamase (ESBL) producing Escherichia coli in children: a case control study. Infect Dis (Lond) 2019;51(11-12):802-9. https://www.ncbi.nlm.nih.gov/pubmed/31429616